HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 2, 2010, Pages 169-183

  Marconi, Peggy ^a   Manservigi, Roberto ^a   Epstein, Alberto L ^b,c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

Amplicon; Attenuated vector; Defective vector; HSV 1; Neurotropism

Indexed keywords

G 207; HSV 1716; NP 2; ONCOLYTIC HERPES VIRUS; UNCLASSIFIED DRUG; VIRUS VECTOR;

AMPLICON; BRAIN DISEASE; BRAIN TUMOR; CLINICAL TRIAL; EXPRESSION VECTOR; GENE EXPRESSION; GENE TECHNOLOGY; GENE THERAPY; GENE TRANSFER; GLIOBLASTOMA; HERPES SIMPLEX VIRUS 1; HUMAN; NONHUMAN; PAIN; RECURRENT CANCER; REVIEW; TRANSGENE; VIRUS PARTICLE; VIRUS RECOMBINANT; VIRUS REPLICATION;

EID: 77749246131     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Frampton AR Jr, Goins WF, Nakano K, Burton EA, Glorioso JC: HSV traffcking and development of gene therapy vectors with applications in the nervous system. Gene Ther (2005) 12(11): 891-901.
2. Palmer JA, Branston RH, Lilley CE, Robinson MJ, Groutsi F, Smith J, Latchman DS, Coffn RS: Development and optimization of herpes simplex virus vectors for multiple long-term gene delivery to the peripheral nervous system. J Virol (2000) 74(12):5604-5618.
3. Diefenbach RJ, Miranda-Saksena M, Douglas MW, Cunningham AL: Transport and egress of herpes simplex virus in neurons. Rev Med Virol (2008) 18(1):35-51.
4. McGraw HM, Friedman HM: Herpes simplex virus type 1 glycoprotein E mediates retrograde spread from epithelial cells to neurites. J Virol (2009) 83(10):4791-4799.
5. Uchida H, Shah WA, Ozuer A, Frampton AR Jr, Goins WF, Grandi P, Cohen JB, Glorioso JC: Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: Resistance of HVEM-expressing cells and identifcation of mutations that rescue nectin-1 recognition. J Virol (2009) 83(7):2951-2961.
6. Knipe DM, Cliffe A: Chromatin control of herpes simplex virus lytic and latent infection. Nat Rev Microbiol (2008) 6(3): 211-221.
7. Lu X, Triezenberg SJ: Chromatin assembly on herpes simplex virus genomes during lytic infection. Biochim Biophys Acta (2009):doi:10.1016/j.bbagrm.2009. 08.004.
8. Goins WF, Krisky DM, Wechuck JB, Huang S, Glorioso JC: Construction and production of recombinant herpes simplex virus vectors. Methods Mol Biol (2008) 433:97-113.
9. Burton EA, Fink DJ, Glorioso JC: Replication-defective genomic HSV gene therapy vectors: Design, production and CNS applications. Curr Opin Mol Ther (2005) 7(4):326-336.
10. Todo T: Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci (2008) 13:2060-2064.
11. Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC: Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother (2009) 9(4): 505-517.
12. Hibbitt OC, Wade-Martins R: Delivery of large genomic DNA inserts >100 kb using HSV-1 amplicons. Curr Gene Ther (2006) 6(3):325-336.
13. Frenkel N: The history of the HSV amplicon: From naturally occurring defective genomes to engineered amplicon vectors. Curr Gene Ther (2006) 6(3):277-301.
14. Epstein AL: HSV-1-derived amplicon vectors: Recent technological improvements and remaining diffculties-A review. Mem Inst Oswaldo Cruz (2009) 104(3):399-410.
15. Burton EA, Bai Q, Goins WF, Glorioso JC: Replication-defective genomic herpes simplex vectors: Design and production. Curr Opin Biotechnol (2002) 13(5):424-428.
16. Krisky DM, Wolfe D, Goins WF, Marconi PC, Ramakrishnan R, Mata M, Rouse RJ, Fink DJ, Glorioso JC: Deletion of multiple immediate-early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons. Gene Ther (1998) 5(12):1593-1603.
17. Berto E, Bozac A, Marconi P: Development and application of replication-incompetent HSV-1-based vectors. Gene Ther (2005) 12(Suppl 1):S98-S102.
18. Chattopadhyay M, Walter C, Mata M, Fink DJ: Neuroprotective effect of herpes simplex virus-mediated gene transfer of erythropoietin in hyperglycemic dorsal root ganglion neurons. Brain (2009) 132(4):879-888.
19. V1.7) levels through activation of protein kinase C in painful diabetic neuropathy. J Neurosci (2008) 28(26): 6652-6658.
20. Chattopadhyay M, Mata M, Goss J, Wolfe D, Huang S, Glorioso JC, Fink DJ: Prolonged preservation of nerve function in diabetic neuropathy in mice by herpes simplex virus-mediated gene transfer. Diabetologia (2007) 50(7):1550-1558.
21. Paradiso B, Marconi P, Zucchini S, Berto E, Binaschi A, Bozac A, Buzzi A, Mazzuferi M, Magri E, Navarro-Mora G, Rodi S, et al: Localized delivery of fbroblast growth factor-2 and brain-derived neurotrophic factor reduces spontaneous seizures in an epilepsy model. Proc Natl Acad Sci USA (2009) 106(17):7191-7196.
22. 35-55-induced experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther (2007) 14(1):93-98.
23. Puskovic V, Wolfe D, Wechuck J, Krisky D, Collins J, Glorioso JC, Fink DJ, Mata M: HSV-mediated delivery of erythropoietin restores dopaminergic function in MPTP-treated mice. Mol Ther (2006) 14(5):710-715.
24. Glorioso JC, Fink DJ: Herpes vector-mediated gene transfer in the treatment of chronic pain. Mol Ther (2009) 17(1):13-18.
25. Wolfe D, Hao S, Hu J, Srinivasan R, Goss J, Mata M, Fink DJ, Glorioso JC: Engineering an endomorphin-2 gene for use in neuropathic pain therapy. Pain (2007) 133(1-3):29-38. (Pubitemid 350138306)
26. Wolfe D, Mata M, Fink DJ: A human trial of HSV-mediated gene transfer for the treatment of chronic pain. Gene Ther (2009) 16(4):455-460.
27. Martino S, Marconi P, Tancini B, Dolcetta D, De Angelis MG, Montanucci P, Bregola G, Sandhoff K, Bordignon C, Emiliani C, Manservigi R, et al: A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. Hum Mol Genet (2005) 14(15):2113-2123.
28. Berges BK, Yellayi S, Karolewski BA, Miselis RR, Wolfe JH, Fraser NW: Widespread correction of lysosomal storage in the mucopolysaccharidosis type VII mouse brain with a herpes simplex virus type 1 vector expressing β-glucuronidase. Mol Ther (2006) 13(5):859-869.
29. Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI: Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res (2005) 1052(12):119-129.
30. Corso TD, Torres G, Goulah C, Roy I, Gambino AS, Nayda J, Buckley T, Stachowiak EK, Bergey EJ, Pudavar H, Dutta P, et al: Assessment of viral and non-viral gene transfer into adult rat brains using HSV-1, calcium phosphate and PEI-based methods. Folia Morphol (Warsz) (2005) 64(3):130-144.
31. Hong CS, Goins WF, Goss JR, Burton EA, Glorioso JC: Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-β peptide in vivo. Gene Ther (2006) 13(14):1068-1079.
32. Miki Y, Nonoguchi N, Ikeda N, Coffn RS, Kuroiwa T, Miyatake S: Vascular endothelial growth factor gene-transferred bone marrow stromal cells engineered with a herpes simplex virus type 1 vector can improve neurological defcits and reduce infarction volume in rat brain ischemia. Neurosurgery (2007) 61(3):586-594; discussion 594-1585
33. Ruffni F, Furlan R, Poliani PL, Brambilla E, Marconi PC, Bergami A, Desina G, Glorioso JC, Comi G, Martino G: Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther (2001) 8(16): 1207-1213.
34. Hsu YC, Lee DC, Chiu IM: Neural stem cells, neural progenitors, and neurotrophic factors. Cell Transplant (2007) 16(2):133-150.
35. Marconi P, Zucchini S, Berto E, Bozac A, Paradiso B, Bregola G, Grassi C, Volpi I, Argnani R, Marzola A, Manservigi R, et al: Effects of defective herpes simplex vectors expressing neurotrophic factors on the proliferation and differentiation of nervous cells in vivo. Gene Ther (2005) 12(7):559-569.
36. Cao H, Zhang GR, Wang X, Kong L, Geller AI: Enhanced nigrostriatal neuron-specifc, long-term expression by using neural-specifc promoters in combination with targeted gene transfer by modifed helper virus-free HSV-1 vector particles. BMC Neurosci (2008) 9:37.
37. Kann O, Kovacs R, Njunting M, Behrens CJ, Otahal J, Lehmann TN, Gabriel S, Heinemann U: Metabolic dysfunction during neuronal activation in the ex vivo hippocampus from chronic epileptic rats and humans. Brain (2005) 128(10): 2396-2407.
38. Tetz LM, Rezk PE, Ratcliffe RH, Gordon RK, Steele KE, Nambiar MP: Development of a rat pilocarpine model of seizure/status epilepticus that mimics chemical warfare nerve agent exposure. Toxicol Ind Health (2006) 22(6):255-266.
39. Lehmann TN, Gabriel S, Kovacs R, Eilers A, Kivi A, Schulze K, Lanksch WR, Meencke HJ, Heinemann U: Alterations of neuronal connectivity in area CA1 of hippocampal slices from temporal lobe epilepsy patients and from pilocarpine-treated epileptic rats. Epilepsia (2000) 41(Suppl 6):S190-S194.
40. Compston A: The basis for treatment in multiple sclerosis. Acta Neurol Scand Suppl (2006) 183:41-47.
41. Fernandez O: Combination therapy in multiple sclerosis. J Neurol Sci (2007) 259(1-2):95-103.
42. Furlan R, Brambilla E, Ruffni F, Poliani PL, Bergami A, Marconi PC, Franciotta DM, Penna G, Comi G, Adorini L, Martino G: Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infltrating lymphocytes. J Immunol (2001) 167(3):1821-1829.
43. Martino G, Poliani PL, Marconi PC, Comi G, Furlan R: Cytokine gene therapy of autoimmune demyelination revisited using herpes simplex virus type-1-derived vectors. Gene Ther (2000) 7(13):1087-1093.
44. Furlan R, Poliani PL, Marconi PC, Bergami A, Ruffni F, Adorini L, Glorioso JC, Comi G, Martino G: Central nervous system gene therapy with interleukin-4 inhibits progression of ongoing relapsing-remitting autoimmune encephalomyelitis in Biozzi AB/H mice. Gene Ther (2001) 8(1):13-19.
45. Ruffni F, Furlan R, Poliani PL, Brambilla E, Marconi PC, Bergami A, Desina G, Glorioso JC, Comi G, Martino G: Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther (2001) 8(16): 1207-1213.
46. Anesti AM, Peeters PJ, Royaux I, Coffn RS: Effcient delivery of RNA interference to peripheral neurons in vivo using herpes simplex virus. Nucleic Acids Res (2008) 36(14):e86.
47. Goins WF, Goss JR, Chancellor MB, de Groat WC, Glorioso JC, Yoshimura N: Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain. Gene Ther (2009) 16(4):558-569.
48. Zhou Z, Peng X, Hao S, Fink DJ, Mata M: HSV-mediated transfer of interleukin-10 reduces infammatory pain through modulation of membrane tumor necrosis factor α in spinal cord microglia. Gene Ther (2008) 15(3):183-190.
49. Hao S, Mata M, Glorioso JC, Fink DJ: Gene transfer to interfere with TNFα signaling in neuropathic pain. Gene Ther (2007) 14(3):1010-1016.
50. Mata M, Hao S, Fink DJ: Gene therapy directed at the neuroimmune component of chronic pain with particular attention to the role of TNFα. Neurosci Lett (2008) 437(3): 209-213.
51. Goss JR, Gold MS, Glorioso JC: HSV vector-mediated modifcation of primary nociceptor afferents: An approach to inhibit chronic pain. Gene Ther (2009) 16(4):493-501.
52. Lee JY, Fink DJ, Mata M: Vector-mediated gene transfer to express inhibitory neurotransmitters in dorsal root ganglion reduces pain in a rodent model of lumbar radiculopathy. Spine (Phila Pa 1976) (2006) 31(14):1555-1558.
53. Liu J, Wolfe D, Hao S, Huang S, Glorioso JC, Mata M, Fink DJ Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain. Mol Ther (2004) 10(1):57-66.
54. Burton EA, Glorioso JC: Multi-modal combination gene therapy for malignant glioma using replication-defective HSV vectors. Drug Discov Today (2001) 6(7):347-356.
55. Mizuno H, Yanoma S, Nishimura G, Hattori S, Ito T, Okudera K, Tsukuda M: Therapeutic effciency of IL-2 gene transduced tumor vaccine for head and neck carcinoma. Cancer Lett (2000) 152(2):175-185.
56. Toda M, Martuza RL, Rabkin SD: Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factor. Mol Ther (2000) 2(4):324-329.
57. Kanno H, Hattori S, Sato H, Murata H, Huang FH, Hayashi A, Suzuki N, Yamamoto I, Kawamoto S, Minami M, Miyatake S, et al: Experimental gene therapy against subcutaneously implanted glioma with a herpes simplex virus-defective vector expressing interferon-γ. Cancer Gene Ther (1999) 6(2):147-154.
58. Krisky DM, Marconi PC, Oligino TJ, Rouse RJ, Fink DJ, Cohen JB, Watkins SC, Glorioso JC: Development of herpes simplex virus replication-defective multigene vectors for combination gene therapy applications. Gene Ther (1998) 5(11):1517-1530.
59. Marconi P, Tamura M, Moriuchi S, Krisky DM, Niranjan A, Goins WF, Cohen JB, Glorioso JC: Connexin 43-enhanced suicide gene therapy using herpesviral vectors. Mol Ther (2000) 1(1):71-81.
60. Wolfe D, Niranjan A, Trichel A, Wiley C, Ozuer A, Kanal E, Kondziolka D, Krisky D, Goss J, Deluca N, Murphey-Corb M, et al: Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates. Gene Ther (2004) 11(23):1675-1684.
61. Puskovic V, Wolfe D, Goss J, Huang S, Mata M, Glorioso JC, Fink DJ: Prolonged biologically active transgene expression driven by HSV LAP2 in brain in vivo. Mol Ther (2004) 10(1):67-75.
62. Rasmussen M, Kong L, Zhang GR, Liu M, Wang X, Szabo G, Curthoys NP, Geller AI: Glutamatergic or GABAergic neuron-specifc, long-term expression in neocortical neurons from helper virus-free HSV-1 vectors containing the phosphate-activated glutaminase, vesicular glutamate transporter-1, or glutamic acid decarboxylase promoter. Brain Res (2007) 1144:19-32.
63. Glorioso JC, Mata M, Fink DJ: Exploiting the neurotherapeutic potential of peptides: Targeted delivery using HSV vectors. Expert Opin Biol Ther (2003) 3(8):1233-1239.
64. Martins I, Pinto M, Wilson SP, Lima D, Tavares I: Dynamic of migration of HSV-1 from a medullary pronociceptive centre: Antinociception by overexpression of the preproenkephalin transgene. Eur J Neurosci (2008) 28(10):2075-2083.
65. Jeyaretna DS, Rabkin SD, Martuza RL: Oncolytic herpes simplex virus therapy for peripheral nerve tumors. Neurosurg Focus (2007) 22(6):E4.
66. Haseley A, Alvarez-Breckenridge C, Chaudhury AR, Kaur B: Advances in oncolytic virus therapy for glioma. Recent Pat CNS Drug Discov (2009) 4(1):1-13.
67. Todo T, Rabkin SD, Martuza RL: Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors. Cancer Gene Ther (2000) 7(6):939-946.
68. Miyatake S, Martuza RL, Rabkin SD: Defective herpes simplex virus vectors expressing thymidine kinase for the treatment of malignant glioma. Cancer Gene Ther (1997) 4(4):222-228.
69. Kanai R, Tomita H, Hirose Y, Ohba S, Goldman S, Okano H, Kawase T, Yazaki T: Augmented therapeutic effcacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma. Hum Gene Ther (2007) 18(1):63-73.
70. Kramm CM, Chase M, Herrlinger U, Jacobs A, Pechan PA, Rainov NG, Sena-Esteves M, Aghi M, Barnett FH, Chiocca EA, Breakefeld XO: Therapeutic effciency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther (1997) 8(17):2057-2068.
71. Bannazadeh Baghi H, Bamdad T, Soleimanjahi H: The effect of herpes simplex virus virion host shutoff gene-A new suicide gene-On tumor cells. Iran Biomed J (2009) 13(3):185-189.
72. Jones FE, Smibert CA, Smiley JR: Mutational analysis of the herpes simplex virus virion host shutoff protein: Evidence that VHS functions in the absence of other viral proteins. J Virol (1995) 69(8):4863-4871.
73. Dambach MJ, Trecki J, Martin N, Markovitz NS: Oncolytic viruses derived from the γ34.5-deleted herpes simplex virus recombinant R3616 encode a truncated UL3 protein. Mol Ther (2006) 13(5):891-898.
74. Ward SL, Scheuner D, Poppers J, Kaufman RJ, Mohr I, Leib DA. In vivo replication of an ICP34.5 second-site suppressor mutant following corneal infection correlates with in vitro regulation of eIF2α phosphorylation. J Virol (2003) 77(8): 4626-4634.
75. Farassati F, Yang AD, Lee PW: Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol (2001) 3(8):745-750.
76. Mahller YY, Rangwala F, Ratner N, Cripe TP: Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants. Pediatr Blood Cancer (2006) 46(7):745-754.
77. Smith KD, Shao MY, Posner MC, Weichselbaum RR: Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: Strategies for clinical application. Future Oncol (2007) 3(5):545-556.
78. Brown SM, MacLean AR, Aitken JD, Harland J: ICP34.5 infuences herpes simplex virus type 1 maturation and egress from infected cells in vitro. J Gen Virol (1994) 75(12):3679-3686.
79. Orvedahl A, Alexander D, Talloczy Z, Sun Q, Wei Y, Zhang W, Burns D, Leib DA, Levine B: HSV-1 ICP34.5 confers neurovirulence by targeting the Beclin 1 autophagy protein. Cell Host Microbe (2007) 1(1):23-35.
80. Alexander DE, Ward SL, Mizushima N, Levine B, Leib DA: Analysis of the role of autophagy in replication of herpes simplex virus in cell culture. J Virol (2007) 81(22):12128-12134.
81. Rampling R, Cruickshank G, Papanastassiou V, Nicoll J, Hadley D, Brennan D, Petty R, MacLean A, Harland J, McKie E, Mabbs R et at: Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther (2000) 7(10):859-866.
82. Detta A, Harland J, Hanif I, Brown SM, Cruickshank G: Proliferative activity and in vitro replication of HSV1716 in human metastatic brain tumours. J Gene Med (2003) 5(8):681-689.
83. 134.5 mutant 1716. J Neurovirol (2008) 14(1):28-40.
84. Shah AC, Benos D, Gillespie GY, Markert JM: Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas. J Neurooncol (2003) 65(3):203-226.
85. GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res (2006) 12(22):6737-6747.
86. Fukuhara H, Todo T: Oncolytic herpes simplex virus type 1 and host immune responses. Curr Cancer Drug Targets (2007) 7(2):149-155.
87. Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F, Tsurumi T, Nishiyama Y: Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther (2007) 14(11):918-926.
88. Nagano S, Perentes JY, Jain RK, Boucher Y: Cancer cell death enhances the penetration and effcacy of oncolytic herpes simplex virus in tumors. Cancer Res (2008) 68(10):3795-3802.
89. Hardcastle J, Kurozumi K, Dmitrieva N, Sayers MP, Ahmad S, Waterman P, Weissleder R, Chiocca EA, Kaur B: Enhanced antitumor effcacy of vasculostatin (Vstat120) expressing oncolytic HSV-1. Mol Ther (2010) 18(2):285-294.
90. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL: Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther (2008) 16(6):1041-1047.
91. Ino Y, Saeki Y, Fukuhara H, Todo T: Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor effcacy. Clin Cancer Res (2006) 12(2): 643-652.
92. Wong RJ, Chan MK, Yu Z, Ghossein RA, Ngai I, Adusumilli PS, Stiles BM, Shah JP, Singh B, Fong Y: Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12. Clin Cancer Res (2004) 10(13):4509-4516.
93. Guffey MB, Parker JN, Luckett WS Jr, Gillespie GY, Meleth S, Whitley RJ, Markert JM: Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther (2007) 14(1):45-56.
94. Currier MA, Gillespie RA, Sawtell NM, Mahller YY, Stroup G, Collins MH, Kambara H, Chiocca EA, Cripe TP: Effcacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther (2008) 16(5): 879-885.
95. Fulci G, Breymann L, Gianni D, Kurozomi K, Rhee SS, Yu J, Kaur B, Louis DN, Weissleder R, Caligiuri MA, Chiocca EA: Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci USA (2006) 103(34):12873-12878. (Pubitemid 44298654)
96. Aghi M, Chou TC, Suling K, Breakefeld XO, Chiocca EA: Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. Cancer Res (1999) 59(16): 3861-3865.
97. Patterson AV, Saunders MP, Greco O: Prodrugs in genetic chemoradiotherapy. Curr Pharm Des (2003) 9(26):2131-2154.
98. Lazear E, Carf A, Whitbeck JC, Cairns TM, Krummenacher C, Cohen GH, Eisenberg RJ: Engineered disulfde bonds in herpes simplex virus type 1 gD separate receptor binding from fusion initiation and viral entry. J Virol (2008) 82(2):700-709.
99. Stiles KM, Milne RS, Cohen GH, Eisenberg RJ, Krummenacher C: The herpes simplex virus receptor nectin-1 is down-regulated after trans-interaction with glycoprotein D. Virology (2008) 373(1):98-111.
100. Kamiyama H, Zhou G, Roizman B: Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor. Gene Ther (2006) 13(7):621-629.
101. Zhou G, Ye GJ, Debinski W, Roizman B: Engineered herpes simplex virus 1 is dependent on IL13Rα 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA (2002) 99(23):15124-15129.
102. Conner J, Braidwood L, Brown SM: A strategy for systemic delivery of the oncolytic herpes virus HSV1716: Redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein. Gene Ther (2008) 15(24):1579-1592.
103. Menotti L, Cerretani A, Hengel H, Campadelli-Fiume G: Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol (2008) 82(20):10153-10161.
104. Glass M, Soling A, Messerle M: Tumor-specifc activity of cellular regulatory elements is down-regulated upon insertion into the herpes simplex virus genome. J Neurovirol (2008) Oct 31:1-14.
105. Griffth C, Noonan S, Lou E, Shillitoe EJ: An oncolytic mutant of herpes simplex virus type-1 in which replication is governed by a promoter/enhancer of human papillomavirus type-16. Cancer Gene Ther (2007) 14(12):985-993.
106. Cuchet D, Potel C, Thomas J, Epstein AL: HSV-1 amplicon vectors: A promising and versatile tool for gene delivery. Expert Opin Biol Ther (2007) 7(7):975-995.
107. Gomez-Sebastian S, Gimenez-Cassina A, Diaz-Nido J, Lim F, Wade-Martins R: Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia defciency in human cells. Mol Ther (2007) 15(2):248-254.
108. Lim F, Palomo GM, Mauritz C, Gimenez-Cassina A, Illana B, Wandosell F, Diaz-Nido J: Functional recovery in a Friedreich's ataxia mouse model by frataxin gene transfer using an HSV-1 amplicon vector. Mol Ther (2007) 15(6):1072-1078.
109. Cortes ML, Oehmig A, Perry KF, Sanford JD, Breakefeld XO: Expression of human ATM cDNA in ATM-defcient mouse brain mediated by HSV-1 amplicon vector. Neuroscience (2006) 141(3):1247-1256.
110. Cortes ML, Oehmig A, Saydam O, Sanford JD, Perry KF, Fraefel C, Breakefeld XO: Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Mol Ther (2008) 16(1):81-88.
111. Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Milo LJ Jr, Federoff HJ: HSV amplicon-mediated Aβ vaccination in Tg2576 mice: Differential antigen-specifc immune responses. Neurobiol Aging (2005) 26(4):393-407.
112. Frazer ME, Hughes JE, Mastrangelo MA, Tibbens JL, Federoff HJ, Bowers WJ: Reduced pathology and improved behavioral performance in Alzheimer's disease mice vaccinated with HSV amplicons expressing amyloid-β and interleukin-4. Mol Ther (2008) 16(5):845-853.
113. Corso TD, Torres G, Goulah C, Roy I, Gambino AS, Nayda J, Buckley T, Stachowiak EK, Bergey EJ, Pudavar H, Dutta P, et al: Transfection of tyrosine kinase deleted FGF receptor-1 into rat brain substantia nigra reduces the number of tyrosine hydroxylase expressing neurons and decreases concentration levels of striatal dopamine. Brain Res Mol Brain Res (2008) 139(2):361-366.
114. Sortwell CE, Bowers WJ, Counts SE, Pitzer MR, Fleming MF, McGuire SO, Maguire-Zeiss KA, Federoff HJ, Collier TJ: Effects of ex vivo transduction of mesencephalic reaggregates with Bcl-2 on grafted dopamine neuron survival. Brain Res (2007) 1134(1):33-44.
115. Arvanian VL, Bowers WJ, Anderson A, Horner PJ, Federoff HJ, Mendell LM: Combined delivery of neurotrophin-3 and NMDA receptors 2D subunit strengthens synaptic transmission in contused and staggered double hemisected spinal cord of neonatal rat. Exp Neurol (2006) 197(2):347-352.
116. Jerusalinsky D, Epstein AL: Amplicon vectors as outstanding tools to study and modify cognitive functions. Curr Gene Ther (2006) 6(3):351-360.
117. Cheli V, Adrover M, Blanco C, Ferrari C, Cornea A, Pitossi F, Epstein AL, Jerusalinsky D: Knocking-down the NMDAR1 subunit in a limited amount of neurons in the rat hippocampus impairs learning. J Neurochem (2006) 97(Suppl 1):68-73.
118. Rumpel S, LeDoux J, Zador A, Malinow R: Postsynaptic receptor traffcking underlying a form of associative learning. Science (2005) 308(5718):83-88.
119. Han JH, Kushner SA, Yiu AP, Cole CJ, Matynia A, Brown RA, Neve RL, Guzowski JF, Silva AJ, Josselyn SA: Neuronal competition and selection during memory formation. Science (2007) 316(5823):457-460.
120. Han JH, Yiu AP, Cole CJ, Hsiang HL, Neve RL, Josselyn SA: Increasing CREB in the auditory thalamus enhances memory and generalization of auditory conditioned fear. Learn Mem (2008) 15(6):443-453.
121. Brightwell JJ, Smith CA, Countryman RA, Neve RL, Colombo PJ: Hippocampal overexpression of mutant CREB blocks long-term, but not short-term memory for a socially transmitted food preference. Learn Mem (2005) 12(1):12-17.
122. Barrot M, Wallace DL, Bolanos CA, Graham DL, Perrotti LI, Neve RL, Chambliss H, Yin JC, Nestler EJ: Regulation of anxiety and initiation of sexual behavior by CREB in the nucleus accumbens. Proc Natl Acad Sci USA (2005) 102(23):8357-8362.
123. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL: Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther (2000) 7(10):867-874.
124. Aghi MK, Chiocca EA: Phase Ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol Ther (2009) 17(1):8-9.
125. Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, et al: Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther (2009) 17(1):199-207.
126. -) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study. Gene Ther (2002) 9(6): 398-406.
127. Harrow S, Papanastassiou V, Harland J, Mabbs R, Petty R, Fraser M, Hadley D, Patterson J, Brown SM, Rampling R: HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther (2004) 11(22):1648-1658.
128. Ikeda N, Nonoguchi N, Zhao MZ, Watanabe T, Kajimoto Y, Furutama D, Kimura F, Dezawa M, Coffn RS, Otsuki Y, Kuroiwa T, et al: Bone marrow stromal cells that enhanced fbroblast growth factor-2 secretion by herpes simplex virus vector improve neurological outcome after transient focal cerebral ischemia in rats. Stroke (2005) 36(12):2725-2730.
129. Yenari MA, Zhao H, Giffard RG, Sobel RA, Sapolsky RM, Steinberg GK: Gene therapy and hypothermia for stroke treatment. Ann NY Acad Sci (2003) 993:54-68; discussion 79-81. (Pubitemid 36808432)
130. Moriuchi S, Glorioso JC, Maruno M, Izumoto S, Wolfe D, Huang S, Cohen JB, Yoshimine T: Combination gene therapy for glioblastoma involving herpes simplex virus vector-mediated codelivery of mutant IκBα and HSV thymidine kinase. Cancer Gene Ther (2005) 12(5):487-496.
131. Niranjan A, Wolfe D, Tamura M, Soares MK, Krisky DM, Lunsford LD, Li S, Fellows-Mayle W, DeLuca NA, Cohen JB, Glorioso JC: Treatment of rat gliosarcoma brain tumors by HSV-based multigene therapy combined with radiosurgery. Mol Ther (2003) 8(4):530-542.
132. Niranjan A, Moriuchi S, Lunsford LD, Kondziolka D, Flickinger JC, Fellows W, Rajendiran S, Tamura M, Cohen JB, Glorioso JC: Effective treatment of experimental glioblastoma by HSV vector-mediated TNF α and HSV-TK gene transfer in combination with radiosurgery and ganciclovir administration. Mol Ther (2000) 2(2):114-120.
133. Hadjipanayis CG, Fellows-Mayle W, Deluca NA: Therapeutic effcacy of a herpes simplex virus with radiation or temozolomide for intracranial glioblastoma after convection-enhanced delivery. Mol Ther (2008) 16(11):1783-1788.
134. Chattopadhyay M, Goss J, Wolfe D, Goins WC, Huang S, Glorioso JC, Mata M, Fink DJ: Protective effect of herpes simplex virus-mediated neurotrophin gene transfer in cisplatin neuropathy. Brain (2004) 127(4):929-939.
135. Zhou Z, Peng X, Fink DJ, Mata M: HSV-mediated transfer of artemin overcomes myelin inhibition to improve outcome after spinal cord injury. Mol Ther (2009) 17(7):1173-1179.
136. Natsume A, Mata M, Wolfe D, Oligino T, Goss J, Huang S, Glorioso J, Fink DJ: Bcl-2 and GDNF delivered by HSV-mediated gene transfer after spinal root avulsion provide a synergistic effect. J Neurotrauma (2002) 19(1):61-68.
137. Walwyn WM, Matsuka Y, Arai D, Bloom DC, Lam H, Tran C, Spigelman I, Maidment NT: HSV-1-mediated NGF delivery delays nociceptive defcits in a genetic model of diabetic neuropathy. Exp Neurol (2006) 198(1):260-270.
138. Zhou Z, Peng X, Insolera R, Fink DJ, Mata M: IL-10 promotes neuronal survival following spinal cord injury. Exp Neurol (2009) 220(1):183-190.
139. Miyazato M, Sugaya K, Goins WF, Wolfe D, Goss JR, Chancellor MB, de Groat WC, Glorioso JC, Yoshimura N: Herpes simplex virus vector-mediated gene delivery of glutamic acid decarboxylase reduces detrusor overactivity in spinal cord-injured rats. Gene Ther (2009) 16(5):660-668.